Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 5, 2014, Pages 513-525

  Chiricozzi, Andrea ^a,b   Saraceno, Rosita ^a   Chimenti, Maria Sole ^a   Guttman Yassky, Emma ^c   Krueger, James G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti p19; Biologics; Guselkumab; IL 17; IL 23; IL 23p19; Psoriasis; Th17; Tildrakizumab

Indexed keywords

ANTIPSORIASIS AGENT; APILIMOD; BI 655066; BRIAKINUMAB; GUSELKUMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 6; MK 3222; TILDRAKIZUMAB; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; USTEKINUMAB; CYTOKINE; IL23R PROTEIN, HUMAN; INTERLEUKIN 12P40; INTERLEUKIN RECEPTOR; MONOCLONAL ANTIBODY;

CYTOKINE PRODUCTION; DENDRITIC CELL; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; MOLECULARLY TARGETED THERAPY; NEUTROPHIL; PSORIASIS; REVIEW; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DRUG SCREENING; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KERATINOCYTE; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; BACTERIAL INFECTIONS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; KERATINOCYTES; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PSORIASIS; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TH17 CELLS;

EID: 84906329163     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.889686     Document Type: Review

References (121)

1. D'Elios MM, Del Prete G, Amedei A. Targeting IL-23 in human diseases. Expert Opin Ther Targets 2010;14:759-74
2. Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/ 23 pathways: Generation and characterization of ustekinumab. Nat Biotechnol 2011;29:615-24
3. Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 2008;382:931-41
4. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25
5. Tang C, Chen S, Qian H, et al. Interleukin-23: As a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-24
6. Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15
7. Ma XT, Zhang XJ, Zhang B, et al. Expression and regulation of interleukin-23 subunits in human peripheral blood mononuclear cells and hematopoietic cell lines in response to various inducers. Cell Biol Int 2004;28:689-97
8. Hochrein H, Shortman K, Vremec D, et al. Differential production of IL-12, IFN-Alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001;166:5448-55
9. Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004;101:4560-5
10. Schuetze N, Schoeneberger S, Mueller U, et al. IL-12 family members: Differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrowderived macrophages. Int Immunol 2005;17:649-59
11. Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: Differential regulation of function by specific classes of physiologic stimuli. Blood 2003;102:1753-63
12. Smits HH, van Beelen AJ, Hessle C, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004;34:1371-80
13. Schnurr M, Toy T, Shin A, et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: A novel role for the cAMP pathway. Blood 2005;105:1582-9
14. Liu W, Ouyang X, Yang J, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem 2009;284:24006-16
15. Kray AE, Carter RS, Pennington KN, et al. Positive regulation of IkappaB kinase signaling by protein serine/ threonine phosphatase 2A. J Biol Chem 2005;280:35974-82
16. Chang J, Voorhees TJ, Liu Y, et al. Interleukin-23 production in dendritic cells is negatively regulated by protein phosphatase 2A. Proc Natl Acad Sci USA 2010;107:8340-5
17. Li S, Wang L, Berman MA, et al. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell 2006;24:497-509
18. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708
19. Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz) 2006;54:15-24
20. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42
21. Van De Vosse E, Lichtenauer-Kaligis EG, Van Dissel JT, et al. Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function. Immunogenetics 2003;54:817-29
22. Cho SS, Bacon CM, Sudarshan C, et al. Activation of STAT4 by IL-12 and IFN-Alpha: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996;157:4781-9
23. Bacon CM, Petricoin EF III, Ortaldo JR, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA 1995;92:7307-11
24. Tato CM, Cua DJ. Reconciling id, ego, and superego within interleukin-23. Immunol Rev 2008;226:103-11
25. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006;176:5652-61
26. Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 2003;73(1):49-56
27. Chen Z, Laurence A, Lanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006;103:8137-42
28. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40
29. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
30. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-4
31. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89
32. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74
33. Veldhoen M, Hocking RJ, Flavell RA, et al. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006;7:1151-6
34. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3
35. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7
36. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9
37. Evans HG, Suddason T, Jackson I, et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-Activated monocytes. Proc Natl Acad Sci USA 2007;104:17034-9
38. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7
39. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007;27:660-9
40. Chen Z, Tato CM, Muul L, et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007;56:2936-46
41. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9:650-7
42. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7
43. Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009;182:5296-305
44. Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86:435-43
45. Laggner U, Di Meglio P, Perera G, et al. Identification of a novel pro-inflammatory human skin-homing Vc9Vd2 T cell subset with a potential role in psoriasis. J Immunol 2011;187:2783-93
46. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500
47. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011;35:596-610
48. Roark CL, Simonian PL, Fontenot AP, et al. gammadelta T cells: An important source of IL-17. Curr Opin Immunol 2008;20:353-7
49. Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009;206:299-311
50. Nigam P, Kwa S, Velu V, et al. Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J Immunol 2011;186:745-53
51. Happel KI, Dubin PJ, Zheng M, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 2005;202:761-9
52. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008;14:275-81
53. Shiomi S, Toriie A, Imamura S, et al. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter 2008;13:518-24
54. Burchill MA, Nardelli DT, England DM, et al. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun 2003;71:3437-42
55. Raffatellu M, Santos RL, Verhoeven DE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008;14:421-8
56. Umemura M, Yahagi A, Hamada S, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786-96
57. Burchill MA, Nardelli DT, England DM, et al. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun 2003;71:3437-42
58. Okamoto Yoshida Y, Umemura M, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010;184:4414-22
59. Fedele G, Stefanelli P, Spensieri F, et al. Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression. Infect Immun 2005;73:1590-7
60. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J Invest Dermatol 2013;133:17-26
61. Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis: Evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012;132:2320-1
62. Ingram JT. The approach to psoriasis. Br Med J 1953;2:591-4
63. Baker BS, Swain AF, Griffiths CE, et al. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment. Scand J Immunol 1985;22:471-7
64. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987;116:503-10
65. Valdimarsson H, Baker BS, Jònsdòttir I, et al. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigenš Immunol Today 1995;16:145-9
66. Demidem A, Taylor JR, Grammer SF, Streilein JW. T-lymphocyte-Activating properties of epidermal antigenpresenting cells from normal and psoriatic skin: Evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J Invest Dermatol 1991;97:454-60
67. Menssen A, Trommler P, Vollmer S, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995;155:4078-83
68. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7
69. Griffiths CE, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986;293:731-2
70. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338:320-1
71. Gudjonsson JE, Johnston A, Dyson M, et al. Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-308
72. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87
73. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-Alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9
74. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-14
75. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32
76. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells. Nat Immunol 2009;10:864-71
77. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009;15(9):1013-15
78. Singh TP, Sch'on MP, Wallbrecht K, et al. Involvement of IL-9 in Th17-Associated inflammation and angiogenesis of psoriasis. PLoS One 2013;8:e51752
79. Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5:e14108
80. Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-g, IL-13, IL-17, and IL-22. J Invest Dermatol 2013;133:973-9
81. Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009;206:249-58
82. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-Antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-94
83. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011;3:73ra19
84. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-Alpha production. J Exp Med 2005;202:135-43
85. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-Alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005;102:19057-62
86. Zaba LC, Krueger JG, Lowes MA. Resident and inflammatory dendritic cells in human skin. J Invest Dermatol 2009;129:302-8
87. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-9
88. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
89. Chiricozzi A, Guttman-Yassky E, Suàrez-Fariñas M, et al. Integrative responses to IL-17 and TNF-Alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131(3):677-87
90. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
91. Li J, Chen X, Liu Z, et al. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007;27:330-2
92. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83
93. Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86:435-43
94. Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010;35:645-9
95. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: A randomized-controlled trial. J Clin Immunol 2009;29:210-14
96. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-Alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-9
97. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
98. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30
99. Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011;186:4481-9
100. Hvid H, Teige I, Kvist PH, et al. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: A novel in vivo screening model of psoriasis. Int Immunol 20(8):1097-106
101. Van Der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45
102. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011;186(3):1495-502
103. Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009;129:650-6
104. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010;302:499-505
105. Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm 2006;74:255-82
106. Johnson-Huang LM, Suàrez-Fariñas M, Sullivan-Whalen M, et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010;130:2654-63
107. Haider AS, Lowes MA, Suàrez-Fariñas M, et al. Identification of cellular pathways of type 1, Th17 T cells, and TNF-And inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-20
108. Singh TP, Sch'on MP, Wallbrecht K, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010;184:7257-67
109. Zaba LC, Suàrez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10
110. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-To-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21
111. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
112. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
113. Alexander W. American Academy of Dermatology Cardiovascular Research Technologies 2013 American College of Cardiology. P T 2013;38:288-92
114. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
115. Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/ 23 pathways: Generation and characterization of ustekinumab. Nat Biotechnol 2011;29:615-24
116. Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-To-severe psoriasis. N Engl J Med 2010;362:118-28
117. Lebwohl M, Leonardi C, Griffiths CE, et al. Long-Term safety experience of ustekinumab in patients with moderate-To-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012;66:731-41
118. Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012;7:e35069
119. Available from: Http://clinicaltrials.gov/ ct2/results?term= CNTO+1959+AND+psoriasis
120. Available from: Http://clinicaltrials.gov/ ct2/results?term= BI655066+AND+PSORIASIS
121. Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol 2010;185:7302-8